Psoralidin enhances the sensitivity of breast cancer to cisplatin by targeting Nr1i2.

We evaluated the therapeutic effect of psoralidin combined with cisplatin in a mouse model of breast cancer by H&E, immunohistochemistry and TUNEL staining. Transcriptome analysis, bioinformatics analysis and molecular docking analysis were used to explore the mechanism of psoralidin and cisplatin in improving breast cancer. The results showed that psoralidin could synergistically enhance the inhibitory effect of cisplatin on the proliferation of 4T1 breast cancer cells, promote the apoptosis of 4T1 cells, increase DNA damage and ROS expression. It also inhibited the expression of breast cancer cell proliferation-related molecules and energy metabolism factors related to tumor cell growth. Psoralidin could also synergistically enhance its inhibitory effect on tumor growth in breast cancer mice. Further molecular docking analysis revealed that psoralidin enhanced the killing effect of cisplatin on tumor cells by binding to Nr1i2. These findings provide a clear scientific basis for the enhancement of anticancer sensitivity to cisplatin by psoralidin.